Follows CAR-T cell therapy in adults with lymphoma or leukemia
Observes how CAR-T cells expand and persist in adults with lymphoma or leukemia.
Plain-language title generated from the registry record
Registry title: Bio-CAR-T BS Study
Key facts
- Where
- Brescia, ItalySee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT05366569, who can take part
Where in Italy
- ASST Spedali Civili di BresciaBrescia, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
- Trial code
- NCT05366569
- Record updated
- 30 April 2026
- Original description
The aim of this Study is the evaluation of post-infusion CAR-T (Chimeric Antigen Receptor T Cell) expansion and persistence in patients with DLBCL, PMBCL and ALL undergoing CAR-T therapy; and the feasibility and efficacy of the treatment in the real life practice.Read full original descriptionShow less
Bio-CAR-T Study on Pre and Post-infusion CAR-T Cell Therapy
The aim of this Study is the evaluation of post-infusion CAR-T (Chimeric Antigen Receptor T Cell) expansion and persistence in patients with DLBCL, PMBCL and ALL undergoing CAR-T therapy; and the feasibility and efficacy of the treatment in the real life practice.
Inclusion: Patients with B-cell-ALL (≤ 25 years) or patients with DLBCL (18-70 years) or patients with PMBCL (18-70 years) who were relapsed/refractory after two lines of treatments; Adequate performance status (0 or 1); Adequate organ function; No active or uncontrolled infections; No thrombo-embolisms within the last 6 months; Absence of clinically relevant co-morbidities (e.g., select cardiovascular, neurologic, or immune disorders with organ dysfunction or requiring immunosuppressive treatment in the last 24 months); Life expectancy of at least 3 months.
Exclusion: Active or uncontrolled infections; Presence of clinically relevant co-morbidities (e.g., select cardiovascular, neurologic, or immune disorders with organ dysfunction or requiring immunosuppressive treatment in the last 24 months); Patients with B-cell-ALL > 25 years; Patients with DLBCL <18 or >70 years; Patients with PMBCL <18 or >70 years; Performance status > 1; Thrombo-embolisms within the last 6 months; Life expectancy < 3 months.